FOLH1 and neoplasm: The development of the theranostic agent PSMA-617, a prostate-specific membrane antigen (PSMA) inhibitor with highly specific tumor enhancement and superior pharmacokinetics, has remarkably advanced diagnostics and therapy of prostate cancer [1].